Reata Pharmaceuticals, Inc. (RETA) News Headlines

▮ More

Date

Headline

5/10/2022 6:44:24 AM Reata Pharma Q1 GAAP Net Loss $73.8 Mln Or $2.03/Shr Vs Loss Of $67.5 Mln Or $1.86/Shr Last Year

2/28/2022 6:48:42 AM Reata Pharma FY GAAP Net Loss $297.4 Mln Or $8.19/Shr Vs Loss Of $247.8 Mln Or $7.35/Shr Last Year

1/31/2022 6:49:00 AM Reata Initiates Rolling Submission Of NDA With FDA For Omaveloxolone For Friedreich's Ataxia Treatment

1/25/2022 5:54:30 AM Biotech Stocks Facing FDA Decision In February 2022

1/4/2022 9:55:48 AM What Is Driving Reata Pharmaceuticals Stock Up 10%?

12/9/2021 7:24:20 AM Pre-market Movers: ENSC, RETA, CCNC, PEAR, SYTA…

12/9/2021 1:43:02 AM AZN's Antibody Authorized For COVID-19, RDUS Shrinks, ZYME On Watch, FDA Panel Snubs RETA

12/8/2021 7:48:13 AM Reata Pharma Stock Trading Halted As FDA Discusses Bardoxolone NDA - Quick Facts

12/8/2021 7:40:35 AM Reata Pharma: FDA Advisory Committee To Discuss Bardoxolone For Chronic Kidney Disease Caused By Alport Syndrome

11/29/2021 2:53:36 AM Biotech Stocks Facing FDA Decision In December 2021

8/10/2021 11:38:00 AM Reata Pharma Down 17% On Q2 Net Loss

5/19/2021 7:43:39 AM Reata Says FDA Requests Pre-NDA Meeting For Omaveloxolone To Treat Friedreich's Ataxia - Quick Facts

3/1/2021 6:41:50 AM Reata Pharma FY GAAP Loss Per Share $7.35; Non-GAAP Loss Per Share $4.70

Older Articles